Die FDA hat eine neue Therapie mit Spender-Immunzellen zur Vorbeugung schwerwiegender Komplikationen bei Patienten mit Blutkrebs zugelassen.
Die .gov-Endung kennzeichnet eine offizielle Website.
Vollstaendiger Artikelinhalt
Food and Drug Administration today approved TREGZI, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Haeufig gestellte Fragen
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
